Actuate Therapeutics, Inc. Common stock (ACTU) - Net Assets
Based on the latest financial reports, Actuate Therapeutics, Inc. Common stock (ACTU) has net assets worth $10.94 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.71 Million) and total liabilities ($6.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read ACTU liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.94 Million |
| % of Total Assets | 61.74% |
| Annual Growth Rate | -91.6% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Actuate Therapeutics, Inc. Common stock - Net Assets Trend (2022–2024)
This chart illustrates how Actuate Therapeutics, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Actuate Therapeutics, Inc. Common stock for the complete picture of this company's asset base.
Annual Net Assets for Actuate Therapeutics, Inc. Common stock (2022–2024)
The table below shows the annual net assets of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. For live valuation and market cap data, see Actuate Therapeutics, Inc. Common stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $104.19K | +100.10% |
| 2023-12-31 | $-99.63 Million | -771.69% |
| 2022-12-31 | $14.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Actuate Therapeutics, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5202909900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.00 | 0.02% |
| Other Components | $132.48 Million | 127160.24% |
| Total Equity | $104.19K | 100.00% |
Actuate Therapeutics, Inc. Common stock Competitors by Market Cap
The table below lists competitors of Actuate Therapeutics, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Samsung Climat
KO:006660
|
$69.73 Million |
|
PYRAMID TECHNOPLAST ORD (BSE)
NSE:PYRAMID
|
$69.74 Million |
|
Malee Group Public Company Limited
BK:MALEE
|
$69.74 Million |
|
Simply Better Brands Corp
V:SBBC
|
$69.78 Million |
|
Lu Hai Holding Corp
TW:2115
|
$69.71 Million |
|
Crown Confectionery Co Ltd
KO:264900
|
$69.71 Million |
|
Artifex Mundi SA
WAR:ART
|
$69.69 Million |
|
Pearl Diver Credit Company Inc.
NYSE:PDCC
|
$69.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Actuate Therapeutics, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -99,626,513 to 104,186, a change of 99,730,699.
- Net loss of 27,285,328 reduced equity.
- Share repurchases of 485,172 reduced equity.
- New share issuances of 23,956,800 increased equity.
- Other factors increased equity by 103,544,399.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.29 Million | -26189.05% |
| Share Repurchases | $485.17K | -465.68% |
| Share Issuances | $23.96 Million | +22994.26% |
| Other Changes | $103.54 Million | +99384.18% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Actuate Therapeutics, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 561.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.04x to 561.92x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.99 | $3.00 | x |
| 2023-12-31 | $-6.63 | $3.00 | x |
| 2024-12-31 | $0.01 | $3.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Actuate Therapeutics, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26189.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 89.44x
- Recent ROE (-26189.05%) is below the historical average (-8774.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -135.92% | 0.00% | 0.00x | 1.38x | $-21.64 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.78 Million |
| 2024 | -26189.05% | 0.00% | 0.00x | 89.44x | $-27.30 Million |
Industry Comparison
This section compares Actuate Therapeutics, Inc. Common stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Actuate Therapeutics, Inc. Common stock (ACTU) | $10.94 Million | -135.92% | 0.62x | $69.73 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more